Bal Pharma board approves Philippines JV investment, warrant allotment to promoter, and director designation changes

Regulatory 12 Aug 2026 · Announced· ✓ Verified

The board meeting on 12 August 2026 approved four substantive resolutions: (1) Q1 FY2026–27 unaudited standalone and consolidated financial results; (2) redesignation of Ravindra Kumar Kothari (DIN 03418320) from Non-Executive Director to Whole-Time Director, signalling operational leadership strengthening; (3) redesignation of Virupakshaya Himesh (DIN 08554422) from Whole-Time Director to Non-Executive Director, a complementary governance recalibration; (4) investment proposal in a new joint venture entity to be incorporated in the Republic of the Philippines, indicating international expansion; and (5) allotment of 10,00,000 (10 lakh) warrants to Shailesh Siroya (Promoter) on…

Why it mattersPromoter warrant allotment on preferential basis triggers SEBI (ICDR) 2018 compliance for pricing and disclosure; cross-border JV structuring requires FDI/RBI clearance review and tax planning under India-Philippines treaty framework.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals